TENX
Tenax Therapeutics, Inc. NASDAQ Listed Apr 4, 1994$2.32
+25.41%
vs $1.85
Mkt Cap $91.0M
52w Low $1.38
5.5% of range
52w High $18.32
50d MA $11.48
200d MA $12.09
P/E (TTM)
-1.6x
EV/EBITDA
—
P/B
0.9x
Debt/Equity
0.0x
ROE
-54.2%
P/FCF
-2.5x
RSI (14)
11.50
ATR (14)
$0.33
Beta
1.19
50d MA
$11.48
200d MA
$12.09
Avg Volume
7.3M
Tenax Therapeutics, Inc., a specialty pharmaceutical company, engages in identifying, developing, and commercializing products for cardiovascular and pulmonary diseases in the United States and Canada. It develops TNX-103 and TNX-102 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of pulmonary arterial hypertension. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Morrisville, North Carolina.
ONE Copley Parkway · Chapel Hill, NC 27560 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jul 31, 2026 | TNS | -0.38 | -0.35 | +8.2% | 13.70 | +0.4% | +4.6% | -3.6% | -5.6% | +2.0% | +1.0% | — |
| May 12, 2026 | TNS | -0.40 | -0.35 | +12.5% | 12.17 | +0.0% | -2.1% | -0.1% | +0.7% | -3.0% | -1.2% | — |
| Mar 10, 2026 | TNS | -1.26 | -0.38 | +69.8% | 14.51 | +1.6% | +0.8% | -2.9% | -2.5% | +1.0% | +8.5% | — |
| Nov 12, 2025 | TNS | -1.33 | -0.40 | +69.9% | 6.99 | -1.7% | -4.3% | +6.1% | +3.5% | +4.6% | -4.8% | — |
| Aug 13, 2025 | TNS | -0.50 | -0.27 | +46.0% | 5.91 | -1.5% | +0.7% | +0.3% | +0.7% | +0.2% | -0.7% | — |
| May 14, 2025 | TNS | -0.48 | -0.28 | +41.7% | 5.68 | +1.2% | +0.4% | +3.3% | +2.2% | -0.3% | +1.2% | — |
| Mar 25, 2025 | TNS | -0.52 | -0.18 | +65.4% | 6.26 | +7.2% | -2.1% | +0.8% | +5.0% | +0.9% | -2.9% | — |
| Nov 13, 2024 | TNS | -1.38 | -0.19 | +86.2% | 4.75 | +2.1% | +4.0% | -1.4% | -0.8% | +0.6% | -1.9% | — |
| Aug 13, 2024 | TNS | -1.99 | -1.83 | +8.0% | 4.03 | -0.7% | -2.0% | +1.3% | +4.8% | +1.4% | -2.6% | — |
| May 14, 2024 | TNS | -2.40 | -3.12 | -30.0% | 3.47 | +4.0% | +3.5% | -1.1% | +0.0% | +6.2% | -2.7% | — |
| Mar 28, 2024 | TNS | -8.14 | -12.98 | -59.5% | 4.24 | -2.1% | -9.9% | +1.3% | +6.2% | -7.1% | +0.0% | — |
| Nov 13, 2023 | TNS | -7.20 | -6.40 | +11.1% | 49.60 | -17.7% | -18.5% | -1.2% | -15.8% | -9.3% | -5.2% | — |
| Aug 14, 2023 | AMC | -0.10 | -4.00 | -3900.0% | 23.36 | +9.6% | +2.7% | +8.0% | +1.9% | +10.6% | +13.2% | — |
| May 15, 2023 | AMC | -0.37 | -12.00 | -3143.2% | 26.56 | +0.9% | -13.6% | +1.4% | +4.1% | +2.3% | +5.8% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 11 | Chardan Capital Markets | Downgrade | Buy → Neutral | $5 | $1.38 | $1.44 | +4.3% | +17.4% | +6.2% | +6.4% | -1.6% | -5.0% |
| Aug 11 | Evercore ISI | Downgrade | Outperform → In-line | $5 | $1.38 | $1.44 | +4.3% | +17.4% | +6.2% | +6.4% | -1.6% | -5.0% |
| Jul 28 | Canaccord Genuity | Initiates | Buy | $35 | $16.19 | $16.47 | +1.7% | -2.4% | -6.2% | +1.9% | -9.3% | +4.6% |
| Jul 22 | Evercore ISI | Initiates | Outperform | $39 | $15.72 | $15.92 | +1.3% | -5.9% | -1.0% | -0.8% | +11.4% | -2.4% |
| Jun 22 | Chardan Capital Markets | Initiates | Buy | $27 | $12.00 | $12.50 | +4.2% | +2.1% | +11.3% | -5.2% | -0.3% | +4.3% |
| Mar 16 | Guggenheim | Maintains | Buy → Buy | — | $13.84 | $14.42 | +4.2% | +1.0% | +8.5% | +2.6% | -4.2% | -4.1% |
| Dec 17 | Guggenheim | Maintains | Buy → Buy | — | $11.16 | $11.30 | +1.3% | +5.6% | +8.7% | +2.2% | -4.9% | -4.0% |
| Aug 14 | Guggenheim | Maintains | Buy → Buy | — | $5.91 | $5.82 | -1.5% | +0.7% | +0.3% | +0.7% | +0.2% | -0.7% |
| Feb 20 | Roth MKM | Maintains | Buy → Buy | — | $4.15 | $4.23 | +1.9% | -3.9% | +9.0% | -6.2% | -2.5% | -0.8% |
| Nov 13 | Roth MKM | Maintains | Buy → Buy | — | $12.48 | $25.04 | +100.6% | +297.4% | -18.5% | -1.2% | -15.8% | -9.3% |
| May 18 | Ladenburg Thalmann | Upgrade | Neutral → Buy | — | $15712.00 | $15936.00 | +1.4% | -1.2% | +3.7% | +2.4% | -0.2% | +1.2% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Aug 24, 2026 | ADAR1 Capital Management, LLC10% | — | Buy | 107,374 | $1.75 | $188K | 4,853,818 | +25.41% | — |
| Aug 21, 2026 | ADAR1 Capital Management, LLC10% | — | Buy | 716,369 | $1.77 | $1.3M | 4,746,444 | +25.41% | — |
| Aug 20, 2026 | ADAR1 Capital Management, LLC10% | — | Buy | 202,124 | $1.78 | $360K | 4,030,075 | +25.41% | — |
8-K
Tenax Therapeutics, Inc. -- 8-K Filing
Aug 10
8-K · 2.02
!! High
Tenax Therapeutics, Inc. -- 8-K 2.02: Earnings Results
Jul 31
8-K
Tenax Therapeutics, Inc. -- 8-K Filing
Jul 2
8-K · 2.02
!! High
Tenax Therapeutics, Inc. -- 8-K 2.02: Earnings Results
May 12
8-K
Tenax Therapeutics, Inc. -- 8-K Filing
Tenax Therapeutics' CFO previously led Triangle Pharmaceuticals through its acquisition by Gilead Sciences, demonstrating experience navigating pharma M&A transactions that could benefit Tenax shareholders.
Apr 22
8-K
Unknown — 8-K Filing
TENX's achievement of randomization targets in its Phase 3 LEVEL study positions potential approval within 18 months, while concurrent LEVEL-2 initiation signals confidence in the drug's viability and reduces development risk for investors.
Mar 10
Institutional (13F) — Top 0
All ↗
No 13F holders found.
Mutual Funds / ETFs (N-PORT) — Top 3
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | Ultra-Small Company Fund | 44,900 | $718K | Mar 2026 |
| 2 | BNY Mellon Small Cap Multi-Strategy Fund | 10,321 | $123K | May 2026 |
| 3 | Russell 2000(R) 1.5x Strategy Fund | 7 | $102 | Jun 2026 |
Valuation
Market Cap
$91.0M
Enterprise Value
-$6.6M
P/E (TTM)
-1.56x
Forward P/E
—
PEG Ratio
-0.55x
P/B
0.94x
P/S
—
P/FCF
-2.54x
EV/EBITDA
—
Shares Out
39.2M
Financials (TTM)
Revenue
$0
Net Income
-$64.9M
EBITDA
-$65.8M
Free Cash Flow
-$35.8M
Op Cash Flow
-$35.8M
EPS Basic
$-1.34
EPS Diluted
$-1.49
EPS Forward
$-1.56
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$104.2M
Total Liab.
$7.2M
Total Equity
$97.1M
Cash
$97.6M
LT Debt
$0
Book Value/Sh
$2.48
Debt/Equity
0.00x
Current Ratio
14.56
Quick Ratio
14.56
Returns & Growth
ROE
-54.2%
ROA
-50.5%
ROIC
-58.1%
Rev Growth YoY
+0.0%
EPS Growth YoY
-16.5%
Price Returns
2W
+34.1%
1M
-87.3%
3M
-84.6%
6M
-85.1%
12M
-68.8%
Technicals
52W High
$18.32
52W Low
$1.38
50d MA
$11.48
200d MA
$12.09
RSI (14)
11.50
ATR (14)
$0.33
Beta
1.19
Avg Volume
7.3M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$25.00
High
$25.00
Low
$25.00
Median
$25.00
Data updated apr 27, 2026 4:27am
· Source: financialmodelingprep.com